Prognostic factors and overall survival among patients with ovarian cancer in the pre-PARP inhibitor era: the OCRWE-Finland study
In the pre-PARP inhibitor era, the absence versus presence of visible residual disease post-debulking surgery was associated with improved OS in stage III, but not stage IV HGSOC. First-line bevacizumab seemed to be beneficial in patients with stage III HGSOC and visible residual disease.
Authors
- Annika Auranen (ORCID: https://orcid.org/0000-0002-9678-4684)
- B. Mascialino (ORCID: https://orcid.org/0000-0003-4154-4728)
- Outi Isomeri (ORCID: https://orcid.org/0009-0009-8460-8913)
- Nichola Roebuck
- Mikko Loukovaara (ORCID: https://orcid.org/0000-0002-4372-2367)
- Sari Käkelä
- J Idänpään-Heikkilä (ORCID: https://orcid.org/0000-0003-3762-5357)
- Mari Lahelma (ORCID: https://orcid.org/0000-0002-4845-0196)
- Heini Rauhamaa
- Riikka‐Leena Leskelä (ORCID: https://orcid.org/0000-0002-9255-2958)
- Sakari Hietanen (ORCID: https://orcid.org/0000-0003-4734-4743)
Institutions
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Turku University Hospital (FI)
- ImmunoGen (United States) (US)
- Public Health Institute (US)
- Glaxosmithkline (Finland) (FI)
- Tampere University Hospital (FI)
- GlaxoSmithKline (Italy) (IT)
- Tampere University (FI)
- GlaxoSmithKline (Germany) (DE)
- Etelä-Karjalan sosiaali ja terveyspiiri (FI)
Publication Details
- Journal
- Acta Oncologica
- Published
- 2024-10-16
- DOI
- https://doi.org/10.2340/1651-226x.2024.40324
- Citations
- 2
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.07